Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Graft vs Host Disease 1

Interventions

pembrolizumab 9trastuzumab deruxtecan 5trametinib 4dabrafenib 4zanubrutinib 3nilotinib 3fludarabine 3Trastuzumab 3Dexamethasone 3Cyclophosphamide 3tucatinib 2tisagenlecleucel 2selinexor 2relatlimab 2pemigatinib 2larotrectinib 2ipatasertib 2erdafitinib 2entrectinib 2enfortumab vedotin 2defactinib 2daratumumab 2blinatumomab 2binimetinib 2belzutifan 2axicabtagene ciloleucel 2atezolizumab 2TIC10 compound 2Sunitinib 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has announcements × Prednisone × Clear all
NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Janssen Research & Development, LLC

Phase 2 Completed
265 enrolled 21 charts 2 FDA
Plasma cell

Multiple Myeloma

NCT02953678 2021-11-24

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Incyte Corporation

Phase 2 Completed
71 enrolled 24 charts 1 FDA

Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡